Have you or your loved ones been diagnosed with community acquired pneumonia?

You may be eligible to participate in a community acquired pneumonia clinical trial.

Have you or your loved ones been diagnosed with community acquired pneumonia? You may be eligible to participate in a community acquired pneumonia clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Community Acquired Pneumonia Clinical Trial
NCT02517489 | Phase 3 | Interventional

Have you or your loved ones been diagnosed with community acquired pneumonia?

You may be eligible to participate in a community acquired pneumonia clinical trial.

Have you or your loved ones been diagnosed with community acquired pneumonia? You may be eligible to participate in a community acquired pneumonia clinical trial.

Completed

Male & Female

18 Years +

This study has recruited 952 Participants

Mortality of severe Community-Acquired Pneumonia (CAP) has not declined over time and is between 25 and 30% in sub-groups of patients. Corticosteroids (CTx) could down-regulate pulmonary and systemic inflammation, accelerate clinical resolution and decrease the rate of inflammation-associated systemic complications. Two recent meta-analyses suggest a positive effect on severe CAP day 28 survival when CTx are added to standard therapy. However they are based on only four trials gathering less than 300 patients, of which only one was positive. Recently published guidelines do not recommend CTx as part of CAP treatment. Therefore a well-powered trial appears necessary to test the hypothesis that CTx - and more specifically hydrocortisone - could improve day 28 survival of critically-ill patients with severe CAP, severity being assessed either on a Pulmonary Severity Index ≥ 130 (Fine class V) or by the use of mechanical ventilation or high-FiO2 high-flow oxygen therapy. A phase-III multicenter add-on randomized controlled double-blind superiority trial assessing the efficacy of hydrocortisone vs. placebo on Day 28 all-causes mortality, in addition to antibiotics and supportive care, including the correction of hypoxemia. Randomization will be stratified on: (i) centers; (ii) use of mechanical ventilation at the time of inclusion.